Cargando…

AB053. Labeling of prostate tumor-specific replication-selective oncolytic adenoviruses with radioactive 125I: inhibitory effects on prostate cancer cell

BACKGROUND: The authors established a 125I-labeled replication-selective oncolytic adenovirus and human telomerase reverse transcriptase/prostate-specific antigen (125I-RSOAds-hTERT/PSA) oncolytic adenovirus marker and investigated the effects of different labeling conditions. This study also explor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Lin, Han, Conghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565601/
http://dx.doi.org/10.21037/tau.2017.s053
_version_ 1783258411832442880
author Hao, Lin
Han, Conghui
author_facet Hao, Lin
Han, Conghui
author_sort Hao, Lin
collection PubMed
description BACKGROUND: The authors established a 125I-labeled replication-selective oncolytic adenovirus and human telomerase reverse transcriptase/prostate-specific antigen (125I-RSOAds-hTERT/PSA) oncolytic adenovirus marker and investigated the effects of different labeling conditions. This study also explored the possible mechanism whereby 125I-RSOAds-hTERT/PSA inhibited the proliferation of prostate cancer cells. METHODS: N-bromosuccinimide (NBS) was used as an oxidant for 125I labeling, and various concentrations of oncolytic viruses and NBS were prepared to determine the optimal conditions for labeling. The effects of the amount of 125I, reaction time, pH, and reaction volume on the labeling rate of the 125I-RSOAds-hTERT/PSA oncolytic adenovirus marker were measured. Radioactive oncolytic adenoviruses were isolated and purified by column chromatography; the radiochemical purities of the 125I-RSOAds-hTERT/PSA marker at different times were detected by paper chromatography. After the addition of radioactive iodine-labeled prostate cancer-specific oncolytic adenoviruses to prostate cancer cells, changes in the inhibitory rate were measured by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assays. RESULTS: The radiochemical purity of the 125I-RSOAds-hTERT/PSA marker was >95%, and the marker was stable (93–94%) after storage at 4 °C for 7 days. The optimal conditions were 0.5 µL of 125I (about 0.2 mCi, 7.4 MBq), 25 µg of NBS, 100 µL of 8×10(9) viral protein (VP)/mL 125I-RSOAds-hTERT/PSA virus solution, 3 min of reaction time, pH 7.5, and 120 µL PBS. Radioactive iodine-labeled prostate cancer-specific oncolytic adenoviruses inhibited the proliferation of prostate cancer cells significantly. CONCLUSIONS: Radioactive 125I labeling of the hTERT/PSA dual-regulated prostate cancer-specific oncolytic adenovirus is feasible, and the radiochemical purity of the marker was stable under defined conditions. Radioactive iodine-labeled prostate cancer-specific replication-selective oncolytic adenoviruses significantly inhibited prostate cell growth.
format Online
Article
Text
id pubmed-5565601
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-55656012017-09-01 AB053. Labeling of prostate tumor-specific replication-selective oncolytic adenoviruses with radioactive 125I: inhibitory effects on prostate cancer cell Hao, Lin Han, Conghui Transl Androl Urol Printed Abstracts BACKGROUND: The authors established a 125I-labeled replication-selective oncolytic adenovirus and human telomerase reverse transcriptase/prostate-specific antigen (125I-RSOAds-hTERT/PSA) oncolytic adenovirus marker and investigated the effects of different labeling conditions. This study also explored the possible mechanism whereby 125I-RSOAds-hTERT/PSA inhibited the proliferation of prostate cancer cells. METHODS: N-bromosuccinimide (NBS) was used as an oxidant for 125I labeling, and various concentrations of oncolytic viruses and NBS were prepared to determine the optimal conditions for labeling. The effects of the amount of 125I, reaction time, pH, and reaction volume on the labeling rate of the 125I-RSOAds-hTERT/PSA oncolytic adenovirus marker were measured. Radioactive oncolytic adenoviruses were isolated and purified by column chromatography; the radiochemical purities of the 125I-RSOAds-hTERT/PSA marker at different times were detected by paper chromatography. After the addition of radioactive iodine-labeled prostate cancer-specific oncolytic adenoviruses to prostate cancer cells, changes in the inhibitory rate were measured by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assays. RESULTS: The radiochemical purity of the 125I-RSOAds-hTERT/PSA marker was >95%, and the marker was stable (93–94%) after storage at 4 °C for 7 days. The optimal conditions were 0.5 µL of 125I (about 0.2 mCi, 7.4 MBq), 25 µg of NBS, 100 µL of 8×10(9) viral protein (VP)/mL 125I-RSOAds-hTERT/PSA virus solution, 3 min of reaction time, pH 7.5, and 120 µL PBS. Radioactive iodine-labeled prostate cancer-specific oncolytic adenoviruses inhibited the proliferation of prostate cancer cells significantly. CONCLUSIONS: Radioactive 125I labeling of the hTERT/PSA dual-regulated prostate cancer-specific oncolytic adenovirus is feasible, and the radiochemical purity of the marker was stable under defined conditions. Radioactive iodine-labeled prostate cancer-specific replication-selective oncolytic adenoviruses significantly inhibited prostate cell growth. AME Publishing Company 2017-08 /pmc/articles/PMC5565601/ http://dx.doi.org/10.21037/tau.2017.s053 Text en 2017 Translational Andrology and Urology. All rights reserved.
spellingShingle Printed Abstracts
Hao, Lin
Han, Conghui
AB053. Labeling of prostate tumor-specific replication-selective oncolytic adenoviruses with radioactive 125I: inhibitory effects on prostate cancer cell
title AB053. Labeling of prostate tumor-specific replication-selective oncolytic adenoviruses with radioactive 125I: inhibitory effects on prostate cancer cell
title_full AB053. Labeling of prostate tumor-specific replication-selective oncolytic adenoviruses with radioactive 125I: inhibitory effects on prostate cancer cell
title_fullStr AB053. Labeling of prostate tumor-specific replication-selective oncolytic adenoviruses with radioactive 125I: inhibitory effects on prostate cancer cell
title_full_unstemmed AB053. Labeling of prostate tumor-specific replication-selective oncolytic adenoviruses with radioactive 125I: inhibitory effects on prostate cancer cell
title_short AB053. Labeling of prostate tumor-specific replication-selective oncolytic adenoviruses with radioactive 125I: inhibitory effects on prostate cancer cell
title_sort ab053. labeling of prostate tumor-specific replication-selective oncolytic adenoviruses with radioactive 125i: inhibitory effects on prostate cancer cell
topic Printed Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565601/
http://dx.doi.org/10.21037/tau.2017.s053
work_keys_str_mv AT haolin ab053labelingofprostatetumorspecificreplicationselectiveoncolyticadenoviruseswithradioactive125iinhibitoryeffectsonprostatecancercell
AT hanconghui ab053labelingofprostatetumorspecificreplicationselectiveoncolyticadenoviruseswithradioactive125iinhibitoryeffectsonprostatecancercell